Eli Lilly | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.18B 349M 2025-03
Abbott USD 6.95B 419M 2025-06
ALKERMES USD 521.2M 121.39M 2025-06
Amgen USD 8.03B 782M 2025-06
AstraZeneca USD 7.06B 1.83B 2025-06
Baxter International USD 2.29B 530M 2025-03
Biogen USD 2.76B 160.5M 2025-06
Bristol-Myers Squibb USD 12.6B 1.72B 2025-06
Drreddys Laboratories INR 9B 7.91B 2025-06
Eli Lilly USD 3.38B 282.6M 2025-06
Gilead Sciences USD 5.14B 2.78B 2025-06
GlaxoSmithKline GBP 3.6B 865M 2025-06
Glaxosmithkline GBP 3.6B 271M 2025-06
J&J USD 38.47B 32.35B 2025-03
Medtronic USD 2.22B 978M 2025-04
Merck USD 8.01B 622M 2025-06
Neurocrine Biosciences USD 264M 69.9M 2025-06
Novartis USD 6.66B 410M 2025-06
Novartis USD 6.66B 4.8B 2025-06
Novo Nordisk A/S 18.44B 5.78B 2025-06
Perrigo USD 454.2M 44.3M 2025-06
Pfizer USD 1.64B 208M 2025-06
Prestige Brands USD 139.5M 41.62M 2025-06
Regeneron Pharmaceuticals USD 2B 1.09B 2025-06
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 15.36B 7.37B 2025-06
Sanofi 15.36B 7.92B 2025-06
United Therapeutics USD 1.59B 306.8M 2025-06
Zoetis USD 1.44B 286M 2025-06


Eli Lilly Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Sep 2025.